Sanofi (NASDAQ:SNY) Hits New 1-Year Low – Should You Sell?

Sanofi (NASDAQ:SNY)’s share price reached a new 52-week low on Friday. The stock traded as low as $40.68 and last traded at $40.7150, with a volume of 210330 shares trading hands. The stock had previously closed at $40.94.

Wall Street Analyst Weigh In

SNY has been the subject of a number of research reports. Morgan Stanley set a $49.00 target price on shares of Sanofi in a research note on Wednesday, July 8th. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 29th. Royal Bank Of Canada started coverage on Sanofi in a report on Tuesday, September 8th. They set a “sector perform” rating for the company. HSBC reissued a “buy” rating on shares of Sanofi in a research report on Thursday, September 10th. Finally, Weiss Ratings downgraded Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $49.50.

Sanofi Price Performance

The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64. The stock has a market capitalization of $98.99 billion, a price-to-earnings ratio of 21.37, a PEG ratio of 1.28 and a beta of 0.35. The stock’s 50 day simple moving average is $43.77 and its 200-day simple moving average is $44.28.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 30th. The company reported $2.41 EPS for the quarter. The company had revenue of $13.36 billion for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The business’s revenue for the quarter was up 16.0% compared to the same quarter last year. During the same quarter last year, the company earned $3.24 EPS. On average, analysts expect that Sanofi will post 5.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Sanofi

Hedge funds have recently bought and sold shares of the business. QRG Capital Management Inc. raised its holdings in Sanofi by 12.9% during the second quarter. QRG Capital Management Inc. now owns 138,522 shares of the company’s stock valued at $5,909,000 after buying an additional 15,800 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its stake in shares of Sanofi by 0.7% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 53,426 shares of the company’s stock worth $2,279,000 after acquiring an additional 351 shares in the last quarter. Tidal Investments LLC boosted its stake in shares of Sanofi by 21.5% during the 2nd quarter. Tidal Investments LLC now owns 165,289 shares of the company’s stock worth $7,051,000 after acquiring an additional 29,283 shares in the last quarter. Archford Capital Strategies LLC acquired a new position in shares of Sanofi during the 2nd quarter valued at about $1,417,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Sanofi during the 2nd quarter valued at about $375,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi is a global healthcare company headquartered in France that develops, manufactures and markets prescription medicines and vaccines. Its portfolio serves patients across areas including immunology, rare diseases, rare blood disorders, neurology, oncology and inflammatory conditions, as well as other specialty-care and general-medicine categories.

The company is also a major vaccine producer through its vaccines business, which supplies products for diseases such as influenza, polio, pertussis, meningitis and dengue.